Yes, with conditions. Most research peptides are not federally controlled substances: a text search of DEA's own alphabetical list of controlled substances turns up none of the names commonly sold as laboratory reagents, so selling or possessing them as research chemicals is lawful on that score. But the same molecule becomes an unapproved new drug under the Food, Drug and Cosmetic Act the moment it is intended for human use, a question decided by objective intent (labeling, marketing, the circumstances of a sale), not by the words printed on a vial.
As of November 7, 2026. This article describes United States federal law and published agency actions as of that date. It is general information, not legal advice; the rules differ by state and change over time, and anyone with a specific question should consult a lawyer licensed in their jurisdiction.
| Statute or section | What it does | Source |
|---|---|---|
| 21 U.S.C. 321(g)(1) | Defines "drug," including anything intended to treat or prevent disease, or to affect body structure or function | law.cornell.edu |
| 21 U.S.C. 321(p)(1) | Defines "new drug": not generally recognized by experts as safe and effective for its labeled use | law.cornell.edu |
| 21 U.S.C. 355(a) | Bars introducing any new drug into interstate commerce without an effective FDA approval | law.cornell.edu |
| 21 U.S.C. 331(a), (d) | Prohibits introducing adulterated, misbranded, or 355-violating articles into interstate commerce | law.cornell.edu |
| 21 U.S.C. 333(a)(1) | General penalty for a 331 violation: up to one year imprisonment, a fine up to $1,000, or both | law.cornell.edu |
| 21 U.S.C. 333(e)(1), (4) | Separate felony, up to five years, for distributing human growth hormone ("somatrem, somatropin, or an analogue of either") for non-approved human use | law.cornell.edu |
| 21 U.S.C. 812(a), (b)(1) | Establishes the five Controlled Substances Act schedules and the Schedule I findings | law.cornell.edu |
| 21 CFR 201.128 | Defines "intended use" by objective intent: labeling, advertising, and the circumstances of distribution | law.cornell.edu |
Which federal law governs research peptides?
The Food, Drug and Cosmetic Act (FD&C Act) matters most. It defines "drug," at 21 U.S.C. 321(g)(1), to cover anything "intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals" or "intended to affect the structure or any function of the body of man or other animals." Nothing in that definition turns on chemical structure or label wording; it turns on intent.
A peptide meeting that definition without FDA approval is a "new drug" under 321(p)(1): one "not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling thereof." Section 355(a) bars introducing "any new drug" into interstate commerce "unless an approval of an application" is in effect, and 331(a) and (d) prohibit introducing an adulterated, misbranded, or 355-violating article. A 331 violation carries, under 333(a)(1), imprisonment of "not more than one year" or a fine of "not more than $1,000," or both.
None of this depends on Controlled Substances Act scheduling. A peptide can sit entirely outside DEA's jurisdiction and still be an unapproved new drug once someone sells it for human use; the two systems ask different questions, and a lab acquiring a reagent has to clear both.
Are research peptides controlled substances?
Separately, the Controlled Substances Act establishes "five schedules of controlled substances, to be known as schedules I, II, III, IV, and V," at 21 U.S.C. 812(a). Schedule I requires findings that a substance "has a high potential for abuse," "has no currently accepted medical use in treatment in the United States," and lacks "accepted safety for use... under medical supervision" (812(b)(1)). The binding, current schedules sit in 21 CFR part 1308, not the statute text.
A text search of DEA's "Controlled Substances, Alphabetical Order" list finds none of the names sold as research chemicals, including BPC-157, TB-500, ipamorelin, CJC-1295, sermorelin, TH9507, NN9535, LY3298176, melanotan, kisspeptin, GHK, NAD, selank, semax, or somatropin. None of these research peptides appears on the current list as a federally controlled substance.
Human growth hormone has its own, narrower statute outside the CSA. Section 333(e)(1) makes it a felony to knowingly distribute, or possess with intent to distribute, human growth hormone for a human use beyond an FDA-authorized, physician-ordered treatment of "a disease or other recognized medical condition," defined at 333(e)(4) as "somatrem, somatropin, or an analogue of either of them." A GHRH analog such as TH9507 is not somatropin; whether it counts as an "analogue" under this statute is unresolved.
What decides whether a peptide is a drug or a reagent?
The line between a lawful reagent and an unapproved drug is drawn by 21 CFR 201.128, FDA's "intended uses" regulation. It defines intended use as "the objective intent of the persons legally responsible for the labeling of an article," shown by "labeling claims, advertising matter, or oral or written statements," by the product's "design or composition," and by "circumstances surrounding the distribution of the article." Its one carve-out, for approved drugs prescribed off-label, does not extend to a seller's own marketing.
"Research Use Only" has exactly one defined meaning in FDA regulation, and it was not written for peptide reagents. 21 CFR 809.10(c) exempts certain in vitro diagnostic products from premarket requirements when "prominently" labeled "For Research Use Only. Not for use in diagnostic procedures." FDA's 2013 guidance treats "soliciting or marketing the product for clinical diagnostic use" as inconsistent with that label. That principle, a label does not settle intended use, is what FDA applied to the peptide sellers below. See what Research Use Only means for the regulation's full wording.
What does FDA's 503A compounding list have to do with it?
A separate FDA system governs which bulk drug substances a compounding pharmacy may use: a substance qualifies under 503A if it meets a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. "Category 2" lists substances FDA has decided not to add because of "significant safety risks relating to the use of these substances in compounding pending further evaluation." The current table includes GHRP-2, GHRP-6, and ipamorelin acetate (added September 29, 2023, for immunogenicity risk tied to aggregation or impurities), and kisspeptin-10 (same date, similar concerns).
That differs from a withdrawn nomination. AOD-9604, BPC-157, CJC-1295, epitalon, GHK-Cu, KPV, MOTS-c, and semax were nominated and then withdrawn by the nominator, which is not a safety finding either way. See what FDA's 503A bulk substances lists mean for how category 1 and category 3 differ.
FDA's Pharmacy Compounding Advisory Committee met July 23 and 24, 2026, on new nominations: BPC-157, KPV and TB-500 for wound healing, MOTS-c for obesity and osteoporosis, on day one; emideltide, semax, and epitalon, for conditions including insomnia and migraine, on day two. The page posts briefing materials, but no vote has been published, and committee advice is non-binding regardless.
What did FDA actually enforce against peptide sellers in 2026?
Two 2026 warning letters show the intended-use analysis applied to actual sellers. On August 24, 2026, FDA's Center for Drug Evaluation and Research warned Peptide Partners LLC over a line that included a GLP-1 class product line (three compounds), SS-31, a TH9507 product, PT-141, and a reconstitution solution. FDA pointed to website claims, spanning bone health, brain cell activity, blood sugar, appetite, retina protection, liver health, and sexual function, citing FD&C Act sections 201(g)(1), 201(p), 505(a), and 301(d) (321(g)(1), 321(p), 355(a), and 331(d) in the U.S. Code): "Despite statements on your product labeling marketing your products 'for research use only' and 'not for human or veterinary use,' evidence obtained from your website establishes that your products are intended to be drugs for human use."
On June 17, 2026, the same center warned Wholesale Peptide over Prostamax and Gonadorelin, citing claims about prostate inflammation for one and testosterone production for the other: "Despite statements on your product labeling marketing your products for, 'RESEARCH USE ONLY' and 'not for human consumption,' evidence obtained from your product labeling, including your website establishes that your products are intended to be drugs for human use." Both firms had fifteen business days to respond; neither letter calls the peptides controlled substances. See how to evaluate a research peptide supplier for checking a supplier's documentation.
Do state laws add anything?
Yes. Florida's Drug and Cosmetic Act, at Florida Statutes 499.003, defines "drug" almost identically to the federal definition, an article "intended for use in the diagnosis, cure, mitigation, treatment, therapy, or prevention of disease in humans or other animals," and "includes active pharmaceutical ingredients." Section 499.005 prohibits "the manufacture, repackaging, sale, delivery, or holding or offering for sale of any drug... that is adulterated or misbranded." Illinois runs a parallel statute, 410 ILCS 620, prohibiting the same for "any food, drug, device or cosmetic that is adulterated or misbranded."
Florida adds a mechanism the federal scheme lacks: Florida Statutes 893.035 recites that "new substances are being created which are not controlled under the provisions of this chapter but which have a potential for abuse similar to or greater than that for substances controlled under this chapter," delegating authority to the Attorney General to add substances to Florida's schedules by rule, independent of federal action. A peptide with no DEA status could, in principle, still be scheduled this way at the state level. Other states run comparable statutes; a broader comparison is in state laws on research peptides.
What is settled and what is not?
| Topic | Settled | Not settled |
|---|---|---|
| Controlled substance status | No common research peptide appears on DEA's alphabetical list | Whether a state uses its own scheduling authority, such as Florida's 893.035, on a specific peptide |
| Drug status under the FD&C Act | Intended use is decided objectively under 21 CFR 201.128; FDA applied it against two sellers in 2026 | Not applicable; this is well established and already enforced |
| Human growth hormone felony, 333(e) | Distributing somatropin, somatrem, or "an analogue of either," for non-approved human use is a separate felony | Whether a GHRH analog like TH9507, or a ghrelin receptor agonist, is an "analogue" of somatropin |
| 503A compounding placement | Current category 2 includes GHRP-2, GHRP-6, ipamorelin acetate, and kisspeptin-10, each with a stated safety concern | Outcome of the July 2026 committee review of BPC-157, KPV, TB-500, MOTS-c, emideltide, semax, and epitalon; no vote posted |
| State law | Florida and Illinois each run an FD&C-style statute mirroring the federal drug definition | Whether any state has actually scheduled a named research peptide under its own authority |
| Anti-doping status | USADA states BPC-157 is prohibited for athletes under the WADA list's S0 category | Whether that sport-eligibility rule has any bearing on ordinary legality; it creates no criminal exposure |
Frequently asked questions
Is BPC-157 legal?
As a reagent sold and labeled for research use, it is absent from DEA's list, and its 503A nomination was withdrawn rather than rejected on safety grounds. For athletes, USADA states it "is prohibited under the S0 Non-Approved Substances category of the List" because it "is not approved for human clinical use by the U.S. Food and Drug Administration (FDA) or any other global health authority," a sport-eligibility rule, not a general ban. See BPC-157's legal status and FDA position for its filing history. A reagent seller should produce a certificate of analysis matching the lot, like the one on the BPC-157 listing.
Is possession of a research peptide a crime?
Not under the Controlled Substances Act, since none are scheduled. Section 331's prohibited acts target interstate commerce in adulterated or misbranded drugs, not an individual holding a vial. The one real exposure is 333(e): distributing or possessing with intent to distribute human growth hormone, narrowly defined, for non-approved human use.
Can a lab or individual lawfully purchase research peptides?
Purchasing a peptide sold and labeled as a reagent does not by itself violate these statutes. Exposure runs to the seller: if marketing shows human-use intent under 21 CFR 201.128, the product becomes an unapproved new drug regardless of the label.
Is "Research Use Only" a loophole?
No. The phrase has one defined regulatory meaning, at 21 CFR 809.10(c), written for diagnostic devices, not reagents generally. FDA's RUO guidance says a manufacturer's "objective intent" controls, not the label text, and both 2026 warning letters applied that reasoning.
Does WADA or USADA status change whether a peptide is legal?
No. That status governs sport eligibility, enforced by sport bodies, not criminal or FDA law. USADA's BPC-157 position ties the prohibition to its unapproved status, not to a separate finding that the compound is contraband.
What changed in 2026?
FDA issued two warning letters applying the intended-use standard to research-peptide sellers: Peptide Partners LLC in August, Wholesale Peptide in June. The compounding committee met in July on nominations including BPC-157, TB-500, MOTS-c, KPV, semax, emideltide, and epitalon, with no vote posted as of this writing.
References
- Cornell Law School Legal Information Institute. 21 U.S.C. 321, Definitions. law.cornell.edu
- Cornell Law School Legal Information Institute. 21 U.S.C. 331, Prohibited acts; and 333, Penalties. law.cornell.edu
- Cornell Law School Legal Information Institute. 21 U.S.C. 355, New drugs. law.cornell.edu
- Cornell Law School Legal Information Institute. 21 U.S.C. 812, Schedules of controlled substances. law.cornell.edu
- Cornell Law School Legal Information Institute. 21 CFR 201.128, Meaning of intended uses. law.cornell.edu
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. April 22, 2026. fda.gov
- U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. fda.gov
- U.S. Food and Drug Administration. Warning Letter to Peptide Partners LLC. August 24, 2026. fda.gov
- U.S. Food and Drug Administration. Warning Letter to Wholesale Peptide. June 17, 2026. fda.gov
- Florida Legislature. Florida Statutes 893.035, Control of new substances by rule. leg.state.fl.us
Research use only. Homegrown Peptides products are for laboratory research and are not for human or animal use. Nothing in this article is medical advice.



